A comparative clinical trial on venthamarai chooranam with & without yogasanam for the management of athimetham (Hyperlipidemia) patients reporting at Ayothidoss pandithar hospital of National Institute of Siddha, chennai
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- The outcome of the study will be assessed by reduction in the lipid levels after treatment
研究概览
简要总结
Hyperlipidemia is one among the lifestyle modification disorders Hyperlipidemia means an increase in total cholesterol level which forms the base for many diseases such as coronary heart disease stroke In the siddha concept it may be correlated to the AthimethamIt is mainly due to lifestyle modification unhealthy eating habits less physical activity medical health disorder under any medication Hence considerably more patients of Athimetham have been recorded in the Ayothiyadoss pandithar hospital The Siddha polyherbal formulation Venthamarai chooranamis said to be cost effective and simple formulation Most of the ingredients of venthamarai chooranam have the antioxidant anti hypertensive and hypolipidemic activity Major causes for hyperlipidemia are sedentary lifestyle unhealthy eating habits stress and obesity The improvement in lipid profile with practice of yoga is due to increased hepatic lipase and lipoprotein lipase This would increase the uptake of triglycerides by adipose tissue and affect the lipoprotein metabolism Yogasanam plays an important role in the management of cholesterol levels So I hope Venthamarai chooranam and yogasanam will be effective in the treatment of Athimetham (Hyperlipidemia)
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20.00 Year(s) 至 60.00 Year(s)(—)
- 性别
- All
入选标准
- •Patients satisfying any one of the following criteria Serum total cholesterol (above 200mg/dl) Serum triglycerides (above 150mg/dl) Low density lipoprotein (above 100mg/dl) Patients who are willing to provide blood for investigation before and after treatment Patient willing to sign in the consent form Patients who are willing to attend OPD once in 7 days.
排除标准
- •Chronic renal failure Liver disorder Pregnancy and lactation Drug induced obesity Cardiac vascular disease Malignancy Neurological disease.
结局指标
主要结局
The outcome of the study will be assessed by reduction in the lipid levels after treatment
时间窗: The outcome of the study will be assessed by a reduction in lipid levels after 90 days of treatment
次要结局
未报告次要终点
